Clinical Trial: Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Ranibizumab Therapy for Choroidal Neovascularization Associated With Angioid Streaks

Brief Summary: The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

Detailed Summary: Choroidal neovascularization is a hallmark of angioid streaks, and presumably VEGF-driven. Ranibizumab has been shown to be effective in CNV secondary to age-related macular degeneration. Therefore, we hypothesize that ranibizumab may be efficacious in the treatment of CNV secondary to angioid streaks
Sponsor: University of Illinois at Chicago

Current Primary Outcome: The primary outcome measures for safety and tolerability are the following: • Incidence and severity of ocular adverse events, as identified by eye examination (including visual acuity testing) [ Time Frame: Month 12 ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Proportion of patients that lose fewer than 15 letters from baseline at months 6 and 12 as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters at months 6 and 12 [ Time Frame: Month 6 and 12 ]

Original Secondary Outcome: Same as current

Information By: University of Illinois at Chicago

Dates:
Date Received: November 17, 2009
Date Started: December 2009
Date Completion:
Last Updated: June 28, 2012
Last Verified: June 2012